How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,491 results for

First Generation Sulfonylurea

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Placebo-Controlled, Randomized, SAD Study to Evaluate the Safety, Tolerability, and PK of TBI-223 in Healthy Adults

First Posted : November 29, 2018 Last Update Posted : January 31, 2019 See Sponsor: Global Alliance for TB Drug Development Information provided by (Responsible Party): Global Alliance for TB Drug Development Study Details Study Description Go to Brief Summary: Partially-Blinded, Placebo-Controlled, Randomized, Single Ascending Dose (SAD) with a Food Effect Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults. Condition or disease Intervention/treatment (...) -life. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 19 Years to 50 Years (Adult) Sexes Eligible

2018 Clinical Trials

182. Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma

Recruitment Status : Recruiting First Posted : August 7, 2018 Last Update Posted : January 15, 2019 See Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University Information provided by (Responsible Party): Thomas Jefferson University ( Sidney Kimmel Cancer Center at Thomas Jefferson University ) Study Details Study Description Go to Brief Summary: This pilot phase I trial studies how well durvalumab given with or without metformin works in treating participants with head and neck squamous cell (...) this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Pathologically confirmed head and neck squamous cell carcinoma (HNSCC), with measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Any stage HNSCC of the 1

2018 Clinical Trials

183. A Trial of Personalized Acupuncture, Standardized Acupuncture, Letrozole and Placebo on Live Birth in Women With PCOS

. ClinicalTrials.gov Identifier: NCT03625531 Recruitment Status : Not yet recruiting First Posted : August 10, 2018 Last Update Posted : August 14, 2018 See Sponsor: Hongxia Ma Information provided by (Responsible Party): Hongxia Ma, The First Affiliated Hospital of Guangzhou Medical University Study Details Study Description Go to Brief Summary: This study is a parallel, assessor-blind controlled trial. A total of 1,100 women with PCOS will be recruited from 10 hospitals and randomly allocated into four groups (...) session will last for 30 min, with a maximum of 48 treatment sessions over 16 weeks. Experimental: Standardized acupuncture Two sets of acupuncture points will be alternated every second treatment. The first set consists of CV 3, CV 6, ST 29 bilaterally, SP 6 bilaterally, SP 9 bilaterally, GV 20 and LI 4 bilaterally. The second set consists of 13 needles: ST 25 bilaterally, ST 29 bilaterally, CV 3, CV 6, SP 6 bilaterally, LR 3 bilaterally, PC 6 bilaterally and GV 20. The following points

2018 Clinical Trials

184. DAPA

aged 20-79 are living with Diabetes in MENA region in 2017, Egypt is number 8 in the top 10 countries in number of adults with Diabetes (8.2 million), where Egypt represents 21% of the Diabetics in MENA region. Metformin is used as 1st line oral anti-diabetic drug in most cases. Sulfonylureas (SU) are used as frequent first add-on after failure of metformin monotherapy. Sodium Glucose Co-transporter 2 (SGLT2) inhibitors are a newer class of therapy which has a lower incidence of hypoglycemia (...) . Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03624803 Recruitment Status : Recruiting First Posted : August 10, 2018 Last Update Posted : March 20, 2019 See Sponsor: AstraZeneca Information provided by (Responsible Party): AstraZeneca Study Details Study Description Go to Brief Summary: Approximately 39 million people of adults

2018 Clinical Trials

185. 5-ALA Patch-PDT of Actinic Keratosis on the Upper Extremities

Keratosis on the Upper Extremities The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03606122 Recruitment Status : Recruiting First Posted : July 30, 2018 Last Update Posted : December 5, 2018 See Sponsor: photonamic GmbH & Co (...) . KG Information provided by (Responsible Party): photonamic GmbH & Co. KG Study Details Study Description Go to Brief Summary: This study evaluates the potential usefulness of photodynamic therapy with PD P 506 A in patients with actinic keratosis on the upper extremities for the first time. Condition or disease Intervention/treatment Phase Actinic Keratoses Drug: PD P 506 A Phase 2 Detailed Description: Patients will receive a second PD P 506 A-PDT on all AK lesions 1-2 weeks after the first PDT

2018 Clinical Trials

186. Effect of Drinks Containing Fruit Polyphenol Extracts and Fibre on Postprandial Glycaemia. (Glu-MIX)

remove one or more studies before adding more. Effect of Drinks Containing Fruit Polyphenol Extracts and Fibre on Postprandial Glycaemia. (Glu-MIX) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03572296 Recruitment Status : Completed First Posted : June 28, 2018 Last Update Posted : January 31, 2019 (...) min following the ad libitum meal ] For each VAS, a numerical score between 0 (not at all) and 100 (extremely) mm was obtained. Buccal mouth swab [ Time Frame: One off sample, collected at the first 1 day of study visit ] Future exploratory analysis of lactase activity via the derived allele at the European Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members

2018 Clinical Trials

187. Personalised Medicine in Pre-diabetes and Early Type 2 Diabetes

-diabetes and Early Type 2 Diabetes (PREDICT) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03558867 Recruitment Status : Recruiting First Posted : June 15, 2018 Last Update Posted : June 15, 2018 See Sponsor: Garvan (...) control is crucial in preventing pre-diabetes complications and onset of diabetes, yet clinical practice, backed by randomised trials, reports that many patients treated with standard dietary guidelines or with the first-line treatment of diabetes patients, metformin, do not improve blood glucose control sufficiently. The overarching goal of the present project is to improve the efficacy of metformin mono-therapy in pre-diabetes and early type 2 diabetes. Condition or disease Intervention/treatment

2018 Clinical Trials

188. The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas

remove one or more studies before adding more. The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas (DCLP3) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03563313 Recruitment Status : Active, not recruiting First Posted : June 20, 2018 Last Update (...) deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 14 Years and older (Child, Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year and using insulin for at least 1

2018 Clinical Trials

189. Understanding the Cardiovascular Benefits of the Anti-Diabetes Medication SGLT2 Inhibitors

studies before adding more. Understanding the Cardiovascular Benefits of the Anti-Diabetes Medication SGLT2 Inhibitors The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03560323 Recruitment Status : Recruiting First Posted (...) /exercise, metformin monotherapy, sulfonylurea monotherapy (SU) or combination metformin/SU therapy. Masking: None (Open Label) Primary Purpose: Basic Science Official Title: SGLT2 Inhibitors, Ketones, & Cardiovascular Benefit Actual Study Start Date : January 7, 2019 Estimated Primary Completion Date : December 31, 2021 Estimated Study Completion Date : December 31, 2022 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment

2018 Clinical Trials

190. Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment

for details. ClinicalTrials.gov Identifier: NCT03637400 Recruitment Status : Not yet recruiting First Posted : August 20, 2018 Last Update Posted : August 20, 2018 See Sponsor: Los Angeles Biomedical Research Institute Collaborators: National Institute of Allergy and Infectious Diseases (NIAID) Washington University School of Medicine University of California, Los Angeles Information provided by (Responsible Party): loren g miller, Los Angeles Biomedical Research Institute Study Details Study Description (...) is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 9 Years to 85 Years (Child, Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Age 9 years to 85 years Able to complete

2018 Clinical Trials

191. Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer.

: Recruiting First Posted : August 20, 2018 Last Update Posted : August 31, 2018 See Sponsor: Massachusetts General Hospital Collaborators: Jawaharlal Nehru Medical College National Cancer Institute (NCI) Information provided by (Responsible Party): Tayyaba Hasan,Ph.D., Massachusetts General Hospital Study Details Study Description Go to Brief Summary: Oral cancer in India affects mostly those from the lower socioeconomic groups, due to a higher exposure to risk factors such as the use of tobacco, zarda (...) (NCI) Investigators Layout table for investigator information Principal Investigator: Tayyaba Hasan, PhD Massachusetts General Hospital, Boston More Information Go to Layout table for additonal information Responsible Party: Tayyaba Hasan,Ph.D., Professor of Dermatology, Massachusetts General Hospital ClinicalTrials.gov Identifier: Other Study ID Numbers: 2015P001855 First Posted: August 20, 2018 Last Update Posted: August 31, 2018 Last Verified: August 2018 Layout table for additional information

2018 Clinical Trials

192. A Study to Evaluate the Effect of add-on Pioglitazone or Glimepiride in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by Alogliptin and Metformin Therapy

does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03499704 Recruitment Status : Not yet recruiting First Posted : April 17, 2018 Last Update Posted : January 17, 2019 See Sponsor: Takeda Information provided by (Responsible Party): Takeda Study Details Study Description Go to Brief Summary: The purpose of this study is to compare the efficacy (...) a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 19 Years to 75 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Has a historical diagnosis of type 2 diabetes. Has a body mass index (BMI) of approximately 20 to 30 kilogram per square meter (kg/m^2). Has been

2018 Clinical Trials

193. Empagliflozin-based Quadruple Combination vs Insulin Glarine-based Combination Therapy in Patients With Type 2 Diabetes

number of saved studies (100). Please remove one or more studies before adding more. Empagliflozin-based Quadruple Combination vs Insulin Glarine-based Combination Therapy in Patients With Type 2 Diabetes The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03473262 Recruitment Status : Completed First (...) decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 80 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Sampling Method: Non-Probability Sample Study Population The targeted population consists

2018 Clinical Trials

194. Use of Incretins in Diabetic Patients

a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Sampling Method: Probability Sample Study Population Patients in therapy with DPP-4 inhibitors in addition to sulfonylureas and/or biguanides and/or thiazolidinediones and/or insulin Criteria Inclusion Criteria (...) of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03486964 Recruitment Status : Recruiting First Posted : April 3, 2018 Last Update Posted : April 3, 2018 See Sponsor: University of Pavia Information provided by (Responsible Party): Giuseppe Derosa, University

2018 Clinical Trials

195. A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: Child, Adult, Older Adult Sexes Eligible for Study: All Accepts Healthy Volunteers: No Sampling Method: Non-Probability Sample Study Population Participants diagnosed with type 2 diabetes mellitus (T2DM) and established cardiovascular (CV) disease over a 4-year period 1 April 2013 and 15 May 2017 will be observed. Criteria Inclusion Criteria: First (...) for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03492580 Recruitment Status : Completed First Posted : April 10, 2018 Last Update Posted : August 27, 2018 Sponsor: Janssen Research & Development, LLC

2018 Clinical Trials

196. A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus

Identifier: NCT03467932 Recruitment Status : Recruiting First Posted : March 16, 2018 Last Update Posted : February 27, 2019 See Sponsor: Oramed, Ltd. Collaborator: Integrium Information provided by (Responsible Party): Oramed, Ltd. Study Details Study Description Go to Brief Summary: This is a four-way (Participant, Care Provider, Investigator, Outcomes Assessor) masked (blinded) study designed to explore efficacy of ORMD-0801 when given in different regimens across a dose range for up to 12 weeks (...) glycemic levels and adverse events will be measured using self-monitored blood glucose (SMBG) and recorded in a diary. Treatment Period (Masking will be Participant, Care Provider, Investigator, Outcomes Assessor) Part 1 In the first two weeks of active treatment (Part 1) subjects will receive double-blind therapy according to their randomized regimen (placebo or ORMD-0801) to be taken QHS, BID or TID. Part 2: During Part 2, subjects will remain on fixed doses of ORMD-0801 or matched placebo for 10

2018 Clinical Trials

197. Effects of Dietary Fiber on Glucose Control in Subjects With Type 2 Diabetes Mellitus

adding more. Effects of Dietary Fiber on Glucose Control in Subjects With Type 2 Diabetes Mellitus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03552991 Recruitment Status : Completed First Posted : June 12, 2018 Last Update Posted : June 12, 2018 Sponsor: Samsung Medical Center Collaborators (...) Intervention/treatment Agio arm It is a pilot study based on the proof-of-concept that dietary fiber helps glucose control in patients with type 2 diabetes. As a single-arm study, 'Agiocur Pregranules' (dietary fiber) is administered for 28 days and stopped for next 28 days, in patients with type 2 diabetes. Drug: Agiocur Pregranules 6g before breakfast and 12g after dinner for first 28 days, and no medication for next 28 days for washout Other Name: Agio gran. Outcome Measures Go to Primary Outcome

2018 Clinical Trials

198. The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas (DCLP3 Extension)

of saved studies (100). Please remove one or more studies before adding more. The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas (DCLP3 Extension) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03591354 Recruitment Status : Enrolling by invitation First (...) and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 14 Years and older (Child, Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Successful completion of the original 6-month RCT within the prior 14 days For females

2018 Clinical Trials

199. Bromocriptine for Patients With Schizophrenia and Impaired Glucose Tolerance

. Bromocriptine for Patients With Schizophrenia and Impaired Glucose Tolerance The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03575000 Recruitment Status : Not yet recruiting First Posted : July 2, 2018 Last Update Posted : July 2 (...) psychiatrically stable APD-treated outpatients, at two sites (VA Pittsburgh and Stanford), aged 18 to 60 years old, with schizophrenia and comorbid IGT will be recruited and receive 6 weeks of bromocriptine (flexibly titrated, 2.5-5.0 mg PO daily). Key inclusion criteria are: 1) currently being treated with second generation APDs for 3 or more months with no change in dose in the 1 month prior to enrollment, 2) fasting glucose 100 to 125mg/dL and/or hemoglobin A1c (HbA1c) 5.7-6.4%. Key exclusions are: 1

2018 Clinical Trials

200. A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Subjects With Type 2 Diabetes Mellitus

for details. ClinicalTrials.gov Identifier: NCT03596177 Recruitment Status : Recruiting First Posted : July 23, 2018 Last Update Posted : March 15, 2019 See Sponsor: MedImmune LLC Information provided by (Responsible Party): MedImmune LLC Study Details Study Description Go to Brief Summary: An Exploratory study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Subjects with Type 2 Diabetes Mellitus Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type II (...) members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 30 Years to 75 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Subjects aged ≥ 30 and ≤ 75 years at screening Provision of signed and dated written informed consent (except

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>